Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe completed psoriasis study record is now displayed, including its safety and efficacy objectives, eligibility criteria, outcomes, study locations, and data-sharing details.SummaryDifference100%

- Check16 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedA notification banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe revision label in the footer changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0; the study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the study content with a simple error layout and a Home button. The detailed study information and navigation are no longer visible due to access restrictions.SummaryDifference16%

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.